AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00511654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW823296 tablet
Description: GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.
Study NCT00511654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW823296 matching placebo
Description: Matching placebo tablets will be identical in appearance to the GW823296 tablets.
Study NCT00511654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).
Study NCT00511654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).
Study NCT00369161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (RAD001)
Study NCT00369161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT00369161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Study NCT00369161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Study NCT00942539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intravenous infusion of 0.05 mg/kg of Midalolam
Study NCT02782754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02782754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02782754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02782754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Study NCT02782754 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced dose of radiotherapy
Study NCT00123656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: esomeprazole dosed qam for 8 weeks
Study NCT00123656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone
Description: fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks
Study NCT03972241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foot insole
Description: arch support and toe extension
Study NCT03734445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin Supplement
Description: Subjects will be randomly allocated to a supplementation of vitamin C 1000mg, vitamin D 400 IU and zinc 10 mg or an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
Study NCT03734445 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomly allocated to a supplementation of an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
Study NCT02665923 — intervention group
Intervention type: OTHER
Intervention: Gastric ultrasound
Description: Ultrasound of abdomen to assess antral volume
Study NCT04418089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: The administration of Simvastatin 40 mg in addition to neoadjuvant chemoterapy CAF
Study NCT04418089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: The administration of Placebo capsule 40 mg in addition to neoadjuvant chemoterapy CAF
Study NCT03922841 — intervention group
Intervention type: OTHER
Intervention: Pleural disease management
Description: History, physical examination, pleural drainage, lab/radiographic investigations
Study NCT04606875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Campbell Score
Description: The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations.
Study NCT01111682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: 0.9% normal saline infusion and boluses of mannitol
Study NCT01111682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline
Description: 3% hypertonic saline continuous infusion, with intermittent boluses as needed
Study NCT00897975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red yeast rice
Description: 600 mg 3 capsules bid
Study NCT00897975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: red yeast rice
Description: 600 mg 3 capsules bid
Study NCT00897975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: red yeast rice
Description: 600 mg 3 capsules bid
Study NCT00897975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phytosterol
Description: phytosterol 450 mg 2 tabs bid with food
Study NCT00897975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic lifestyle program
Description: TLC - 12 weeks
Study NCT00897975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic lifestyle program
Description: TLC - 12 weeks
Study NCT00897975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03309124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mashed potatoes
Description: Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
Study NCT03309124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fried French fries
Description: Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
Study NCT00897975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03309124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal skipping
Description: No food given
Study NCT06106074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Tablet, oral
Study NCT06106074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, oral
Study NCT04539379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: intravenous infusion
Study NCT04539379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetolol
Description: intravenous infusion
Study NCT01266993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix (GSK134612 vaccine)
Description: Intramuscular, 1 dose
Study NCT01266993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menjugate
Description: Intramuscular, 1 dose
Study NCT00114309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131-I-TM-601
Description: 131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
Study NCT00114309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-TM601
Description: 131I-TM601, in solution, delivered intracavitarily following surgical resection 6 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
Study NCT00253786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial therapy
Description: Blood glucose control: HbA1c \< 6.2% Blood pressure control: SBP \< 125 mmHg, DBP: \< 75 mmHg Lipid profile: T-cho \< 180 mg/dl, LDL-cho \< 100 mg/dl, HDL-cho >40 mg/dl Dietary intervention: TDEI \< 30 kcal/kg/day, sodium \< 5 g/day, protein \< 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, multivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care
Study NCT00253786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Blood glucose control: HbA1c \< 6.9% Blood pressure control: SBP \< 130 mmHg, DBP: \< 80 mmHg Lipid profile: T-cho \< 200 mg/dl, LDL-cho \< 120 mg/dl, HDL-cho >40 mg/dl, Dietary intervention: TDEI \< 25-30 kcal/kg/day, sodium \< 6 g/day, protein \< 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)
Study NCT01387503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Once randomized to Group 1, patients will be enlisted for liver transplantation at the recruiting Center. Prioritization is encouraged as a waiting time of more than 8 months could cause patients' drop-out from the study
Study NCT03306043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
Study NCT03982888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Stimulation of the nucleus accumbens via 2 electrodes implanted in the brain per patient to reduce self-injurious behaviours.
Study NCT03982888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS
Description: Use of the Medtronic DBS device. DBS device consists of 2 parts:~1. DBS lead, a thin wire with 2 electrical contacts implanted into pre-determined brain regions, and~2. Implantable pulse generator, a small device containing the batter and computer source placed under the skin of the chest to generate electrical pulses
Study NCT02087150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Eustachian Tube Balloon Catheter (ETBC)
Study NCT01254175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHPIV3cp45 Vaccine
Description: 10\^5 TCID\^50 of rHPIV3cp45 vaccine, delivered as nose drops
Study NCT01254175 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo vaccine, delivered as nose drops
Study NCT03146858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin is an anticlotting treatment that targets the other aspect of clot formation known as the coagulation cascade. Enoxaparin or an alternative is recommended as a single does to support PPCI procedure.
Study NCT00955006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA-016-00-VP
Description: Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.
Study NCT00955006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRCHIVADV014-00-VP
Description: A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
Study NCT02019602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling from mother
Description: A blood sample from the mother will be taken within 24 hours before/after the delivery.
Study NCT02019602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling from infant
Description: Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.
Study NCT02019602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling from umbilical cord
Description: A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.
Study NCT02019602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.~* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous Use
Study NCT00206388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolendric acid
Description: IV, 2mg/m2/dose on day 0
Study NCT00206388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: fixed dose of 25mg/m2/dose days 0-27
Study NCT03001401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iDesign
Description: One group will under go standard LASIK using iDesign platform (J\&J, USA). Visual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
Study NCT03001401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMILE
Description: The other group will undergo SMILE for treatment refractive error (Carl Zeiss, Germany). isual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
Study NCT01584830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506)
Description: Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
Study NCT01584830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given 3 weeks on/1 week off (160 mg od po.)
Study NCT04276090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
Description: Patients will undergo surgical hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
Study NCT04276090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion pump floxuridine and dexamethasone
Description: Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump
Study NCT04276090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for colorectal liver metastases
Description: Patients will receive disease-appropriate systemic chemotherapy for colorectal liver metastases (FOLFOX, FOLFIRI, or irinotecan/oxaliplatin, or panitumumab if KRAS/NRAS wild type)
Study NCT04276090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for intrahepatic cholangiocarcinoma
Description: Patients will receive disease-appropriate systemic chemotherapy for intrahepatic cholangiocarcinoma (gemcitabine/oxaliplatin or gemcitabine alone)
Study NCT01644396 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Adalimumab
Study NCT02126436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Participants will receive a course of traditional Chinese acupuncture. Acupuncture will be pragmatic but strict guidelines will be adhered to including:~using a combination of body and auricular acupuncture, treating the opposite limb to amputation and possibly the residual limb, using auricular acupuncture points such as shen men, sympathetic, points corresponding to the lower limb, using body acupuncture points around the stump (depending on tissue health and the patient), mirroring local and distal points by needling them on the opposite limb, points on the lower back taking a segmental approach to dermatomal pain, including points such as LI4 + LR3, LR3, GV20, SP10, electro-acupuncture may be used, retaining the needles for 20-30 minutes, treating twice weekly for four weeks.
Study NCT00719212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
Study NCT03837236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study group
Description: Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
Study NCT01939561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Study NCT01939561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is tablets identically with the Lamotrigine tablets.
Study NCT05041660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual-reality-based training
Description: Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.
Study NCT01699464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286 Ophthalmic Solution 0.7%
Description: Ophthalmic Solution
Study NCT05041660 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Virtual-reality-based training
Description: Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.
Study NCT05041660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhibitory Control Training
Description: Uses an active inhibitory control training which includes a stop signal.
Study NCT05041660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhibitory Control Training
Description: Uses an active inhibitory control training which includes a stop signal.
Study NCT05041660 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Inhibitory Control Training
Description: Uses an inhibitory control training which does not include a stop signal.
Study NCT05041660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized training
Description: Uses a relatively simplistic computerized training.
Study NCT05041660 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Computerized training
Description: Uses a relatively simplistic computerized training.
Study NCT02870764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dan-shen extract
Description: A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza
Study NCT02870764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Study NCT02870764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
Study NCT02870764 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
Study NCT03057067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of pelvic vein varicosities
Description: Embolization of pelvic vein varicosities
Study NCT02445131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
Study NCT02445131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA101
Description: Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg~Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg.
Study NCT02445131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAL-101
Description: Induction: Cycle 2-6: d1-28: 150 mg p.o.~Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o.
Study NCT01230099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Information Team Group
Description: A minimum of two protocolized, interdisciplinary, informational support meetings led by palliative care clinicians will be arranged with family members or other patient surrogates who participate in decision-making for individual chronically critically ill patients.
Study NCT01085084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered per dose and schedule specified in the arm description.
Study NCT01085084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Study NCT01085084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Study NCT03904316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biodesign Otologic graft
Description: Acellular matrix derived from porcine small intestine submucosa
Study NCT03904316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous temporalis fascia
Description: An autologous graft for tympanic membrane repair